Leading the Way in Life Science Technologies

GEN Exclusives

More »


More »

For full access to this article login to GEN Select now.

January 01, 2014 (Vol. 34, No. 1)

Asthma Prescription Numbers Slow Down

Monoclonal Antibodies Lead the Pipeline in the Development of Novel Therapeutics

  • The asthma prescription market is slowing as the leading drugs lose patent protection. But leading market researchers BCC and GBI Research each predict moderate growth until at least 2017, thanks to new market entrants and a disease prevalence that continues to rise globally. BCC figures indicate the market ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.